Boryeong Reports 11% Increase in Q3 Operating Profit... High Growth in Anticancer Drugs and Yonggaksan

Boryung announced on the 25th that its consolidated operating profit for the third quarter of this year was tentatively estimated at 18.5 billion KRW, an increase of 11.06% compared to the same period last year.

Boryung Consumer Healthcare's 'Yonggaksan Cool 50 Packs'.
Photo by Boryung Consumer Healthcare

Sales rose by 5.25% to 208.3 billion KRW compared to the same period last year, while net profit decreased by 45.63% to 12 billion KRW.

Boryung stated that prescription drugs accounted for 83% of sales, growing 7% compared to the same period last year.

In particular, sales of the anticancer drug "Gemza," for which domestic rights were acquired from the multinational pharmaceutical company Lilly in 2020, grew by 114% year-on-year, and sales of the anticancer biosimilar (biopharmaceutical generic) "Onbevzi," for which domestic distribution rights were obtained from Samsung Bioepis, increased by 70% during the same period, driving growth.

However, sales of the diabetes treatment "Trulicity" decreased by 39% year-on-year due to supply instability issues, and sales of the hypertension treatment "Kanarb" product line also declined by 2%.

In the over-the-counter drug sector, the cough and expectorant medicine "Yonggaksan" recorded sales 21% higher than the same period last year.

Boryung said, "We have surpassed 200 billion KRW in sales for four consecutive quarters," and added, "We will continue to expand the proportion of self-produced products to secure profitability."

This content was produced with the assistance of AI translation services.